Radiometabolic treatment of bone-metastasizing cancer: From 186rhenium to 223radium

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 1, 2014, Pages 1-11

  Rubini, Giuseppe ^a   Nicoletti, Adriano ^a   Rubini, Domenico ^a   Asabella, Artor Niccoli ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Bone metastases; Molecular imaging; Myelosuppression; Radionuclide therapy; Radiopharmaceuticals

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PHOSPHORUS 32; RADIUM CHLORIDE RA 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89;

BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

BONE NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; RHENIUM;

EID: 84890531221     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1549     Document Type: Review

References (74)

1. Urch C. The pathophysiology of cancer-induced bone pain: Current understanding. Palliat Med 2004;18:267.
2. Lam MG, De Klerk JM, Van Rijk PP, et al. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 2007;7:381.
3. Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7.
4. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584.
5. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010;40:89.
6. Caraceni A, Chern N, Fainsinger R, et al. Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002;23:239.
7. Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods 2011;55:258.
8. Poulter CA, Cosmatos D, Rubin P, et al. A report of RTOG 8206: A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992;23:207.
9. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. J Am Med Assoc 1995;274:1870.
10. Christo PJ, Mazloomdoost D. Cancer pain and analgesia, Ann N Y Acad Sci 2008;1138:278.
11. Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R. Coll. Radiol.) 2012;24:112.
12. Hobbs RF, McNutt T, Baechler S, et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys 2011;80:1256.
13. Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett 2012;323:135.
14. Silberstein EB. Systemic radiopharmaceuticals therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000; 10:240.
15. Lewington VJ. Bone-seeking radiopharmaceuticals. J Nucl Med 2005;46:38S.
16. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol 2005;6:392.
17. Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934.
18. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 2006; 25:669.
19. Silberstein EB. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 1993; 20(3suppl2):10.
20. Robinson RG. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993; 72(11Suppl):3433.
21. Taylor AJ Jr. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 1994;35:2054.
22. Blake GM, Zivanovic MA, Blaquiere RM, et al. Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases. J Nucl Med 1988;29:549.
23. Fuster D, Herranz D, Vidal-Sicart S, et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 2000;21:623.
24. Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: Report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol) 2001;13:219.
25. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium- 89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805.
26. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation of Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519.
27. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31:33.
28. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336.
29. Nilsson S, Strang P, Ginman C, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005; 29:352.
30. De Klerk JM, Zonnenberg BA, Blijham GH, et al. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res 1997;17:1773.
31. Maxon III HR, Schroder LE, Thomas SR, et al. Re.186(Sn) HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155.
32. Sciuto R, Tofani A, Festa D, et al. Short and long-term effects of 185Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41:647.
33. Han SH, DE Klerk JM, Tan S, et al. The PLACORHEN study: A double-blind, placebo-controlled, randomized radiounclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43:1150.
34. Lam MG, De Klerk JM, Tan S, et al. 186Re-HEDP for metastatic bone pain in breast cancer patients. J Nucl Med 2004;31 Suppl 1:S162.
35. Palmedo H, Bender H, Dierke-Dzierzon C, et al. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med 1999; 24:643.
36. Minutoli F, Herberg A, Spadaro P, et al. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 2006; 50:355.
37. Leondi AH, Souvatzoglou MA, Rapti AS, et al. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. Q J Nucl Med Mol Imaging 2004;48:211.
38. Palmedo M, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869.
39. Furhanghi M, Holmes RA, Volkert WA, et al. Samarium- 153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastastic bone cancer. J Nucl Med 1992;33:1451.
40. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34:1031.
41. Bayouth JE, Macey DJ, Kase LP, et al. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994;35:63.
42. Collins C, Eary JF, Donaldson G, et al. Samarium-153- EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 1993;34:1839.
43. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7:1926.
44. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574.
45. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment complex for treatment of painful bone metatastases in hormone-refractory prostate cancer. Urology 2004;63:940.
46. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999;26:2.
47. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429.
48. Rasulova N, Lyubshin V, Arybzhanov D, et al. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease. World J Nucl Med 2013;12:14.
49. Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006;39:35.
50. Koutsikos J, Leondi A. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008; 35:1392.
51. Marcus CS, Saeed S, Mlikotic A, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002;27:427.
52. Lam MG, Dahmane A, Stevens WH, et al. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008;35:756.
53. Baczyk M, Czepczynski R, Milecki P, et al. 89Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28:245.
54. Sciuto R, Festa A. Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001;66:101.
55. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007; 28:623.
56. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, a-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120.
57. Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control 2012;19:137.
58. Salmon PL, Onischuk YN, Bondarenko OA, et al. Alpha particle doses to cells of the bone remodeling cycle from alpha-particle-emitting bone-seekers: Indications of an antiresorptive effect of actinides. Radiat Res 1999;152:S43.
59. Bruland OS, Nilsson S, Fisher DR, et al. high-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?. Clin Cancer Res 2006;12(20 pt 2):6250s.
60. Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: Dose to normal organs and tissues. Eur J Nucl Med Mol Imaging 2013;40:207.
61. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451.
62. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium- 223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587.
63. Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11:20.
64. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63:189.
65. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride in the treatment of patients with symptomatic bone metastases in castration resistant prostate cancer: A phase III randomized trial (ALSYMPCA). J Clin Oncol 2012;30 (abstract 8).
66. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium- 223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213.
67. Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013;5:1.
68. Chiacchio S, Mazzarri S, Lorenzoni A, et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging 2011;55:431.
69. Sinzinger H, Palumbo B, Ozker K, et al. The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imaging 2011;55:420.
70. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:1023.
71. Cuccurullo V, Cascini GL, Rossi A, et al. Pathophysiological premises to radiotracers for bone metastases. Q J Nucl Med Mol Imaging 2011;55:420.
72. Kelkar SS, Reineke TM. Theranostics: Combining imaging and therapy. Bioconjug Chem 2011;22:1879.
73. Ambrosini V, Fanti M, Fanti S, et al. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011;52 Suppl 2:42S.
74. De Nardo GL, De Nardo SJ. Concepts, consequences and implications of theranosis. Semin Nucl Med 2012;42:147.